期刊文献+

KLF2在肺动脉高压大鼠肺组织中的表达及机制探讨 被引量:4

Expression of KLF2 in pulmonary tissue of rats with pulmonary hypertension and its mechanism
下载PDF
导出
摘要 目的:观察野百合碱(MCT)诱导的肺动脉高压大鼠肺组织中KLF2及其相关因子的表达。方法:腹腔一次性注射MCT制作肺动脉高压大鼠模型,采用RT-PCR及Western blot检测肺组织中KLF2、核因子-κB(NK-κB)、血管内皮生长因子受体2(VEGFR2)、内皮素-1(ET-1)、一氧化氮合酶(eNOS)等各因子的表达变化。采用ELISA方法测定血清白介素-1β(IL-1β)、白介素-6(IL-6)及内皮素-1(ET-1)水平。采用硝酸还原酶法测定血清一氧化氮(NO)含量。结果:MCT组大鼠肺组织中KLF2及eNOS的表达水平较对照组显著降低;而NK-κB、VEGFR2及ET-1的表达水平较对照组显著增高。MCT组大鼠血清中IL-1β、IL-6及ET-1水平变化较对照组显著升高,而NO水平较对照组显著降低。Spearman相关性分析显示:KLF2与血清IL-1β(r=-0.617,P<0.05)、IL-6(r=-0.539,P<0.05)及ET-1(r=-0.881,P<0.05)呈显著负相关,而与NO呈显著正相关(r=0.721,P<0.05)。结论:野百合碱诱导的肺动脉高压大鼠肺组织中KLF2显著降低,KLF2可能参与肺血管内皮细胞炎症反应、血管重构及血管异常收缩等发病过程中。 Objective:To investigate the expression of KLF2 and its related factors in the lung tissues of rats with pulmonary hypertensionⅡnduced by monocrotaline(MCT).Methods:The rat model with pulmonary hypertension was made by one-time intraperitoneal injection of MCT.The expression of KLF2,NF-κB,VEGFR2,ET-1 and eNOS was detected in lung tissues of rats with pulmonary hypertension by RT-PCR and Western blot.The serum levels of IL-1β,IL-6 and ET-1 were measured by ELISA.Serum NO level was detected via nitrate reductase.Results:The expression of KLF2 and eNOS in the MCT group was significantly lower than that in the control group.The expression levels of NF-κB,VEGFR2 and ET-1 were significantly higher than those in the control group.The serum levels of IL-1β,IL-6 and ET-1 in the MCT group were significantly higher than those in the control group,while the level of NO was significantly lower than those in the control group.Spearman correlation analysis showed that KLF2 was negatively correlated with IL-1β(r=-0.617,P<0.05),IL-6(r=-0.539,P<0.05)and ET-1(r=-0.881,P<0.05),while positively correlated with serum NO(r=0.721,P<0.05).Conclusion:KLF2 in pulmonary tissues of rats with pulmonary hypertension induced by MCT is significantly decreased,and KLF2 may be involved in the pathogenesis of pulmonary vascular endothelial cell inflammation,vascular remodeling and abnormal vasoconstriction.
作者 王蕊 尚粉青 叶玉兰 郭瑄 WANG Rui;SHANG Fenqing;YE Yulan(Department of Cardiology,Xi’an Gaoxin Hospital,Xi’an 710075)
出处 《陕西医学杂志》 CAS 2020年第8期919-922,共4页 Shaanxi Medical Journal
基金 国家自然科学基金青年科学基金资助项目(81800397) 陕西省卫生健康科研基金资助项目(2018D005) 西安市科技计划项目[2019114613YX001SF036(2)]。
关键词 肺动脉高压 Kruppel样转录因子 内皮细胞 白介素-1Β 内皮素-1 一氧化氮 Pulmonary hypertension Kruppel-like transcription factor Endothelial cell Interleukin-1β Endothelin 1 Nitric oxide
  • 相关文献

参考文献7

二级参考文献48

  • 1高汉华,刘映峰,钟华英,杨宇.川芎嗪联合西地那非对原发性肺动脉高压导致右心室重塑的影响[J].中国老年学杂志,2014,34(9):2383-2385. 被引量:11
  • 2McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the american college of cardiology foundation task force on expert consensus documents and the american heart association: Developed in collaboration with the american college of chest physicians, american thoracic society, inc., and the pulmonary hypertension association. Circulation, 2009, 119(16): 2250-2294.
  • 3D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med, 1991, 115(5): 343-349.
  • 4Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J, 2007, 30(6): 1103-1110.
  • 5Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med, 2004, 351(16): 1655-1665.
  • 6Nakanishi N, European Society of Cardiology, European Respiratory Society. 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease. Allergol Int, 2011, 60(4): 419-424.
  • 7Hiremath J, Thanikachalam S, Parilda K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controUed trial, J Heart Lung Transplant, 2010, 29(2): 137-149.
  • 8Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized, controlled trial. Circulation, 2013, 127(5): 624-633.
  • 9McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinfl to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. JAm Coll Cardio, 2010, 55(18): 1915-1922.
  • 10McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol, 2003, 41 (2): 293-299.

共引文献51

同被引文献52

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部